One woman with uterine cancer that spread to the brain did well on combined treatment
Original title: Durable disease control following multidisciplinary treatment including pembrolizumab in POLE-mutated dedifferentiated endometrial carcinoma with brain metastases: A case report.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This was seen in only one patient, so it is not yet proven as a treatment.
The short version
This report tells the story of one woman whose uterine cancer spread to her brain and was kept under control for 14 months.
What was studied. Doctors described one 58-year-old woman with a rare, fast-growing uterine cancer. Her cancer had a gene change called POLE and had spread to her brain and lungs.
What they found. She had brain surgery, then radiation. Next she got chemo along with an immune drug called pembrolizumab. Her tumors shrank a lot, her symptoms went away, and she was able to do her normal daily activities again. At 14 months, her cancer had not grown, and she had no serious side effects.
What this means, and what it doesn't
What it could mean: Testing a tumor's genes may help doctors find people who could do well on immune drugs. This may be true even when the cancer has spread to the brain.
What it doesn't mean: This is the story of just one person. It does not prove the treatment will work for others. It is not a new standard of care, and it is not a cure. More research in many people is needed.
Source: PubMed, September 18, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.